Muscle Invasive Urothelial Carcinoma
Advertisement
Durvalumab was granted FDA Priority Review for MIBC, after showing significant survival benefits in the NIAGARA trial.
Robotic cystectomy after neoadjuvant immunotherapy shows higher severe complication rates than surgery alone.
Dr. Li provides background and insights on the implications of his study on oncolytic immunotherapy with nivolumab for MIBC.
IMvigor011 compared the efficacy of atezolizumab with placebo in patients with HR MIBC who remained ctDNA+ post-cystectomy.
The study examined the prognostic value of ctDNA as a biomarker in patients with muscle-invasive bladder cancer.
During the final part of this panel, novel ADCs are explored and analyzed for use in different settings.
During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.
In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored.
In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed.
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered.
The panelists wrap up this peri-operative therapy session with what the envision for the future for sparing bladders.
In this third segment, the panelists discuss bladder-sparing approaches.
The second part of this four-part segment includes conversation about ctDNA in bladder cancer.
The first part of four segments from the panel session on peri-operative therapy in bladder cancer.
The NIAGARA study showed significant survival benefits with perioperative durvalumab for patients with MIBC.
Dr. Drakaki highlights the VOLGA study and its practice-changing potential for patients with muscle-invasive bladder cancer.
Dr. Armstrong reviews a handful of GU studies presented, including NIAGRA and STAMPEDE.
Drs. Karine Tawagi and Christopher Wallis review the SunRISe-1 and AMBASSADOR trials at the ESMO Congress 2024.
Dr. Grande discusses the importance of durvalumab for shifting the MIBC treatment landscape.
Dr. Jensen highlights the single-arm trial design and TOMBOLA's use of ctDNA.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.